{"id":193430,"date":"2026-08-10T12:42:19","date_gmt":"2026-08-10T07:12:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=193430"},"modified":"2026-08-10T12:42:21","modified_gmt":"2026-08-10T07:12:21","slug":"akums-drugs-q1-results-fy27-pat-100-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/","title":{"rendered":"Akums Drugs Q1 FY27 Results: Revenue Rs 1,166 Cr, PAT Rs 100 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Akums Drugs Q1 FY27 results declared August 8, 2026. Revenue Rs 1,166 Cr (+13.93% YoY). PAT Rs 100 Cr (+56.11% YoY). CMP Rs 697.45 (+5.27%).<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/akums\/akums-drugs-and-pharmaceuticals-ltd-share-price-today\">Akums Drugs<\/a> Q1 FY27 results were announced on August 8, 2026, consolidated. Revenue grew +13.93% YoY to Rs 1,166 Cr from Rs 1,024 Cr in Q1 FY26. The broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit stood at Rs 133 Cr (+45.15% YoY). PAT came in at Rs 100 Cr (+56.11% YoY), offering a comprehensive view of how Akums Drugs is navigating the current pharmaceuticals environment.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=akums-drugs-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Akums_Drugs_Q1_FY27_Financial_Highlights\" title=\"Akums Drugs Q1 FY27 Financial Highlights\">Akums Drugs Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Akums_Drugs_Q1_FY27_Performance_Analysis\" title=\"Akums Drugs Q1 FY27 Performance Analysis\">Akums Drugs Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Key_Business_Factors_in_Akums_Drugs_Q1_FY27_Results\" title=\"Key Business Factors in Akums Drugs Q1 FY27 Results\">Key Business Factors in Akums Drugs Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Revenue_Expansion_Driving_Top-Line_Growth\" title=\"Revenue Expansion Driving Top-Line Growth\">Revenue Expansion Driving Top-Line Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Operating_Leverage_and_Margin_Improvement\" title=\"Operating Leverage and Margin Improvement\">Operating Leverage and Margin Improvement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#PAT_Performance_and_Profitability_Trend\" title=\"PAT Performance and Profitability Trend\">PAT Performance and Profitability Trend<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#FY27_Outlook_for_Akums_Drugs\" title=\"FY27 Outlook for Akums Drugs\">FY27 Outlook for Akums Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Akums_Drugs_Stock_Performance_After_Q1_FY27_Results\" title=\"Akums Drugs Stock Performance After Q1 FY27 Results\">Akums Drugs Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Key_Risks_for_Akums_Drugs\" title=\"Key Risks for Akums Drugs\">Key Risks for Akums Drugs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Frequently_Asked_Questions_on_Akums_Drugs_Q1_FY27_Results\" title=\"Frequently Asked Questions on Akums Drugs Q1 FY27 Results\">Frequently Asked Questions on Akums Drugs Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#When_were_Akums_Drugs_Q1_FY27_results_declared\" title=\"When were Akums Drugs Q1 FY27 results declared?\">When were Akums Drugs Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#What_was_Akums_Drugs_revenue_in_Q1_FY27\" title=\"What was Akums Drugs revenue in Q1 FY27?\">What was Akums Drugs revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#What_was_Akums_Drugs_PAT_in_Q1_FY27\" title=\"What was Akums Drugs PAT in Q1 FY27?\">What was Akums Drugs PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#Did_Akums_Drugs_declare_a_dividend_in_Q1_FY27\" title=\"Did Akums Drugs declare a dividend in Q1 FY27?\">Did Akums Drugs declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#What_is_the_FY27_outlook_for_Akums_Drugs\" title=\"What is the FY27 outlook for Akums Drugs?\">What is the FY27 outlook for Akums Drugs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/akums-drugs-q1-results-fy27-pat-100-crore\/#How_did_Akums_Drugs_stock_react_to_Q1_FY27_results\" title=\"How did Akums Drugs stock react to Q1 FY27 results?\">How did Akums Drugs stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Akums_Drugs_Q1_FY27_Financial_Highlights\"><\/span><strong>Akums Drugs Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #ffffff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Akums Drugs Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">1,166<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">1,024<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+13.93%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">133<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">92<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+45.15%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">100<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">64<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+56.11%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\" colspan=\"3\">Consolidated<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Akums_Drugs_Q1_FY27_Performance_Analysis\"><\/span><strong>Akums Drugs Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Akums Drugs Q1 FY27 results reflect strong fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 1,166 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit expanded +45.15% YoY to Rs 133 Cr. This indicates improving cost efficiency and better product mix.<\/p>\n<p>PAT of Rs 100 Cr marks a +56.11% YoY movement in Akums Drugs Q1 FY27 results. Investors monitoring Akums Drugs Q1 FY27 results will note this as a key FY27 performance milestone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Akums_Drugs_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Akums Drugs Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Expansion_Driving_Top-Line_Growth\"><\/span><strong>Revenue Expansion Driving Top-Line Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Akums Drugs Q1 FY27 results show top-line strength with revenue growing +13.93% YoY to Rs 1,166 Cr from Rs 1,024 Cr in Q1 FY26. Steady volume-led growth and disciplined pricing supported the revenue uptick.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Leverage_and_Margin_Improvement\"><\/span><strong>Operating Leverage and Margin Improvement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Akums Drugs Q1 FY27 results improved +45.15% YoY to Rs 133 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Performance_and_Profitability_Trend\"><\/span><strong>PAT Performance and Profitability Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit (PAT) in Akums Drugs Q1 FY27 results stood at Rs 100 Cr ((+56.11% YoY)). Improving PAT trajectory signals strengthening financial health.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was announced alongside Akums Drugs Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Akums_Drugs\"><\/span><strong>FY27 Outlook for Akums Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Akums Drugs is well-positioned to sustain growth momentum through FY27, backed by order visibility, sector tailwinds, and operational improvements. Management guidance points to continued expansion in the pharmaceuticals segment with a focus on margin improvement. Investors tracking Akums Drugs Q1 FY27 results should consult a SEBI-registered financial advisor before making investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Akums_Drugs_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Akums Drugs Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Akums Drugs live price and get daily stock recommendations.<\/em><\/p>\n<p>Akums Drugs shares were trading higher at Rs 697.45 (+5.27%) on August 8, 2026, reflecting investor sentiment on the Akums Drugs Q1 FY27 results and near-term sector outlook. The CMP of Rs 697.45 on the results date reflects broader market and sector sentiment in the pharmaceuticals space.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Akums_Drugs\"><\/span><strong>Key Risks for Akums Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA regulatory actions, pricing pressure, and API cost inflation are core risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Valuation risk if quarterly growth momentum fails to sustain over the next two to three quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Subsidiary-level losses or underperforming overseas operations could drag consolidated PAT lower.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Akums Drugs Q1 FY27 results reflect strong performance with revenue at Rs 1,166 Cr and PAT at Rs 100 Cr on a Consolidated basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Akums_Drugs_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Akums Drugs Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Akums_Drugs_Q1_FY27_results_declared\"><\/span><strong>When were Akums Drugs Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Akums Drugs Q1 FY27 results were declared on August 8, 2026, covering the April to June 2026 quarter on a Consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Akums_Drugs_revenue_in_Q1_FY27\"><\/span><strong>What was Akums Drugs revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Akums Drugs Q1 FY27 results show revenue of Rs 1,166 Cr, +13.93% compared to Rs 1,024 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Akums_Drugs_PAT_in_Q1_FY27\"><\/span><strong>What was Akums Drugs PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in Akums Drugs Q1 FY27 results was Rs 100 Cr, +56.11% year-on-year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Akums_Drugs_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Akums Drugs declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was announced alongside Akums Drugs Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Akums_Drugs\"><\/span><strong>What is the FY27 outlook for Akums Drugs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Management has guided revenue growth and margin improvement for FY27. Sector trends and order visibility will be key monitorables for investors.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Akums_Drugs_stock_react_to_Q1_FY27_results\"><\/span><strong>How did Akums Drugs stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Akums Drugs shares were trading higher at Rs 697.45 (+5.27%) on August 8, 2026 following the Akums Drugs Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Akums Drugs Q1 FY27 results: Revenue Rs 1,166 Cr (+13.93% YoY), PAT Rs 100 Cr (+56.11% YoY). Key highlights, financial analysis and FY27 outlook.<\/p>\n","protected":false},"author":36,"featured_media":193427,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-193430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["193427"],"_edit_lock":["1786345944:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["73"],"rank_math_title":["Akums Drugs Q1 FY27 Results: Revenue Rs 1,166 Cr | PAT Highlights"],"rank_math_description":["Akums Drugs Q1 FY27 results: Revenue Rs 1,166 Cr (+13.93% YoY), PAT Rs 100 Cr (+56.11% YoY). Key highlights, financial analysis and FY27 outlook."],"rank_math_focus_keyword":["Akums Drugs Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35361"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/akums-drugs-q1-results-fy27-pat-100-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/193430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=193430"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/193430\/revisions"}],"predecessor-version":[{"id":193459,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/193430\/revisions\/193459"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/193427"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=193430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=193430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=193430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}